The effects of celecoxib on the proliferation and ultrastructural changes of MDA-MB-231 breast cancer cells
- 22 March 2018
- journal article
- research article
- Published by Taylor & Francis in Ultrastructural Pathology
- Vol. 42 (3) , 289-294
Abstract
This study sought to investigate the effects of celecoxib on the proliferation and morphological changes of triple-negative breast cancer (TNBC) MDA-MB-231 cells. In this study, after MDA-MB-231 cells were treated with a certain concentration of celecoxib, a cell counting kit-8 (CCK-8) proliferation assay was used to detect cell viability. Western blotting was utilized to analyze the expression level of caspase-3, which is an apoptosis-related protein. In addition, the morphological changes in the cells and nuclei were determined with fluorescence and electron microscope. Apoptotic nuclei and obvious cytoplasmic vacuolization were observed with a microscope. Collectively, celecoxib can inhibit the proliferation of MDA-MB-231 cells by increasing caspase-3 expression and causing ultrastructural changes.Keywords
Funding Information
- NSFC (81472765)
This publication has 17 references indexed in Scilit:
- The pathologic characteristics of breast cancer in China and its shift during 1999–2008: A national‐wide multicenter cross‐sectional image over 10 yearsInternational Journal of Cancer, 2012
- Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in VivoCancer Cell International, 2012
- Celecoxib Promotes c-FLIP Degradation through Akt-Independent Inhibition of GSK3Cancer Research, 2011
- Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor–Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma CellsCancer Prevention Research, 2011
- Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cellsOncogene, 2011
- Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtypeCancer Causes & Control, 2011
- Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lungInflammopharmacology, 2009
- Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 InhibitorsJNCI: Journal of the National Cancer Institute, 2006
- Cyclooxygenase-independent down-regulation of multidrug resistance–associated protein-1 expression by celecoxib in human lung cancer cellsMolecular Cancer Therapeutics, 2005
- COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxibThe FASEB Journal, 2001